Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus LUNELLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus LUNELLE.
CU-7 vs LUNELLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
Lunelle is a combination contraceptive injection containing medroxyprogesterone acetate and estradiol cypionate. It suppresses gonadotropin secretion, inhibiting ovulation and thickening cervical mucus to prevent sperm penetration.
50 mg orally once daily
150 mg intramuscular injection on day 5 of menstrual cycle, then every 90 days thereafter.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Terminal elimination half-life of 20-30 hours in healthy adults; prolonged to 40-60 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinically, steady state reached in 4-5 days.
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Primarily renal (~70% as unchanged drug and inactive metabolites), with ~20% biliary/fecal elimination. Minimal dose recovered in feces as parent compound.
Category C
Category C
Contraceptive
Contraceptive